Piperacillin is a new semisynthetic, expanded-spectrum penicillin with marked activity against Pseudomonas aeruginosa. The biliary excretion of piperacillin was studied in patients undergoing cholecystectomy. Concentrations of piperacillin in common duct bile at 35 to 90 min postinfusion of 1-g doses ranged from 31 to 920 ,ug/ml, with a mean (±standard deviation) of 467 ± 363 jig/ml. Gallbladder piperacillin levels at 30 to 75 min postinfusion ranged from 2.2 to 80 ,ug/ml, with a mean of 27 ± 31 ,ug/ml. No correlation occurred with peak serum level of antibiotic, creatinine, bilirubin, or alkaline phosphatase. Significant amounts of piperacillin were excreted via the biliary system.
The pharmacokinetics of piperacillin (sodium 6-[D-(-)-a(4-ethyl-2,3-dioxo-1-piperazinyI carbonylamino) -a-phenylacetamido] penicillinate), a new semisynthetic penicillin with an expanded spectrum against both gram-negative and gram-positive aerobes and anaerobes (5) (6) (7) 10) have been studied in patients with normal renal function (2, 8) The patients were prepared for cholecystectomy by standard procedures. At induction of anesthesia, 1 g of piperacillin was infused intravenously for 30 min. Samples of gallbladder and common duct bile were obtained when the gallbladder was removed and when the common duct was explored. The time after the beginning of infusion at which the samples were obtained was recorded. Serum samples were drawn over a 3-h interval after beginning the infusion.
Bile samples were mixed with 0.1 M phosphate buffer (pH 6) immediately to prevent piperacillin inactivation (A. Dombush, personal communication). Blood samples were centrifuged, and the serum was collected. All samples were stored at -70°C until assayed for piperacillin concentration. Piperacillin concentrations were determined by the paper disk assay method, using Sarcina lutea 9341 as the test organism (4). Patient 5 had been given ampicillin, and, therefore Pseudomonas aeruginosa 3414 was used as the assay organism. Standard test assays performed with the two test organisms yielded similar results.
Every patient had a complete blood count and serum biochemical profile performed before and after the administration of piperacillin.
RESULTS
The serum concentrations of piperacillin after a 1-g intravenous dose are shown in Table 1 . The mean (+ standard deviation) peak level of piperacillin occurred at the end of the 30-min infusion and was 75.3 ± 46.6 Ag/ml. Serum levels decreased rapidly so that by 3 h postinfusion the mean serum level was 11.1 ± 7.1 ,ug/ml.
Common duct and gallbladder biliary concentrations of piperacillin are shown in Tables 2 and  3 , respectively. Piperacillin concentrations of bile samples from the common duct were quite high and exceeded gallbladder concentrations.
Common duct levels of piperacillin at 35 to 90 min postinfusion ranged from 31 to 920 Ag/ml, with a mean concentration during the 55-min period of 467.8 ± 363.4 ,Ag/ml. Gallbladder levels at 30 to 75 min postinfusion ranged from 2.2 to 80 jig/ml, with a mean of 27.2 ± 31 ,Lg/ml during the 45-min period.
Common duct bile levels of piperacillin did not correlate with peak serum levels of pipera- streptococci (5, 6, 10) . These high piperacillin common duct bile levels must, of course, be viewed with the knowledge that our patients had nonobstructed biliary systems. The inability of antimicrobial agents to penetrate into the obstructed biliary tree (1, 9) adds a note of caution to our results. Clinical studies will be needed to show the effectiveness of piperacillin in patients with biliary obstruction.
